Cognition Therapeutics, Inc.
CGTX
$1.20
$0.021.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.00% | 4.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 114.45% | -54.39% | |||
| Operating Income | -114.45% | 54.39% | |||
| Income Before Tax | 32.19% | 26.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 32.19% | 26.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 32.19% | 26.79% | |||
| EBIT | -114.45% | 54.39% | |||
| EBITDA | -114.73% | 54.45% | |||
| EPS Basic | 40.35% | 40.21% | |||
| Normalized Basic EPS | 40.25% | 40.24% | |||
| EPS Diluted | 40.35% | 42.55% | |||
| Normalized Diluted EPS | 40.25% | 40.24% | |||
| Average Basic Shares Outstanding | 13.66% | 22.39% | |||
| Average Diluted Shares Outstanding | 13.66% | 22.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||